<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135091</url>
  </required_header>
  <id_info>
    <org_study_id>NTE001</org_study_id>
    <nct_id>NCT05135091</nct_id>
  </id_info>
  <brief_title>FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy</brief_title>
  <official_title>A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurona Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurona Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to test whether a single stereotactic intracerebral&#xD;
      administration of inhibitory nerve cells into subjects with drug-resistant mesial temporal&#xD;
      lobe epilepsy is safe (frequency of adverse events) and effective (seizure frequency).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo a single stereotactic intracerebral administration of neural cells,&#xD;
      called interneurons, that secrete the inhibitory neurotransmitter gamma-aminobutyric acid&#xD;
      (GABA).&#xD;
&#xD;
      Subjects will then take medicines to partially suppress their immune system (aimed to prevent&#xD;
      the body from rejecting the cells) for 1 year. Safety, tolerability, evidence of neural cell&#xD;
      viability and local inflammation (using MRI scans of the brain), and effects on epilepsy&#xD;
      disease symptoms will be assessed for 2 years post-transplant. Subjects will be followed for&#xD;
      an additional 13 years with quarterly phone contact and annual visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two-stage study. Stage 1 is an open-label, single arm, sequential dose escalation. Stage 2 is a parallel, randomized, 2-arm, sham controlled study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a two-stage study. Stage 1 is open-label and unmasked. Stage 2 is masked with participant, part of investigator team, and outcomes assessor masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of serious or severe AEs</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint of the study is the frequency of serious or severe AEs over the period of 1 year after administration, comparing all subjects treated with NRTX-1001 (Stage 1 + Stage 2) with all subjects who receive sham treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in seizure frequency</measure>
    <time_frame>1 year</time_frame>
    <description>The difference in the median percentage change from baseline in seizure frequency (seizures per 28 days) between subjects that receive NRTX-1001 and those who receive sham treatment, assessed in Stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>1 year</time_frame>
    <description>The difference in the 75% responder rate, e.g., the difference between the fraction of subjects who receive NRTX-1001 and those that receive sham treatment who experience at least a 75% reduction from baseline in seizure frequency, assessed in Stage 2.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis</condition>
  <arm_group>
    <arm_group_label>NRTX-1001 (Stage 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRTX-1001 (Stage 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 20 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator (Stage 2)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Up to 10 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NRTX-1001</intervention_name>
    <description>Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.</description>
    <arm_group_label>NRTX-1001 (Stage 1)</arm_group_label>
    <arm_group_label>NRTX-1001 (Stage 2)</arm_group_label>
    <other_name>GABA-secreting interneurons</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>Sham Comparator.</description>
    <arm_group_label>Sham Comparator (Stage 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, age ≥18 to 55&#xD;
&#xD;
          2. Focal seizures, clinically defined as TLE&#xD;
&#xD;
          3. Has failed to achieve seizure control despite adequate trials of at least 2 ASDs at&#xD;
             appropriate doses&#xD;
&#xD;
          4. Currently on stable doses (at least 1 month) of approved ASDs&#xD;
&#xD;
          5. Single seizure focus confirmed as within one temporal lobe&#xD;
&#xD;
          6. For subjects entering Stage 1, seizure focus is in the non-dominant hemisphere.&#xD;
&#xD;
          7. Seizure frequency averages ≥2 per 28-day period over the 6 months prior to screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Epilepsy due to other and/or progressive neurologic disease&#xD;
&#xD;
          2. Significant other medical condition which would impair safe participation&#xD;
&#xD;
          3. Primary or secondary immunodeficiency&#xD;
&#xD;
          4. Suicide attempt in the past year&#xD;
&#xD;
          5. Severe psychiatric disorders&#xD;
&#xD;
          6. Chronic indwelling intracranial device&#xD;
&#xD;
          7. MRI indicating potential malignant lesion&#xD;
&#xD;
          8. Pregnancy, or currently breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Blum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurona Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Madrid, BS, BA</last_name>
    <phone>650-255-6885</phone>
    <email>sheri.madrid@neuronatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paurene Duramad, PhD</last_name>
    <phone>650-392-0379</phone>
    <email>paurene@neuronatx.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

